High output heart failure

QJM: An International Journal of Medicine

Volumn 102, Issue 4, 2009, Pages 235-241

  Mehta, P A ^a   Dubrey, S W ^b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b HILLINGDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBON DIOXIDE; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPHEDRINE; METARAMINOL; NEBIVOLOL; NEUROHORMONE; NORADRENALIN; PHENYLEPHRINE; VASODILATOR AGENT;

ANEMIA; ARTERIAL PRESSURE; ARTERIOVENOUS FISTULA; ARTERIOVENOUS SHUNT; BERIBERI; BLOOD GAS ANALYSIS; CENTRAL VENOUS PRESSURE; CLINICAL FEATURE; CLINICAL TRIAL; DIET RESTRICTION; DISEASE ASSOCIATION; DYSPNEA; ECHOCARDIOGRAPHY; FATIGUE; FLUID RETENTION; HEART FAILURE; HEART OUTPUT; HORMONAL REGULATION; HUMAN; HYPERCAPNIA; HYPERTHYROIDISM; LUNG EDEMA; OBESITY; PAGET BONE DISEASE; PERIPHERAL EDEMA; PLEURA EFFUSION; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; REVIEW; SEPSIS; SODIUM RESTRICTION; TACHYCARDIA; TACHYPNEA; THORAX RADIOGRAPHY; VASCULAR RESISTANCE; VASODILATATION;

EID: 63549097665     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcn147     Document Type: Review

References (65)

1. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al. Guidelines for the diagnosis and treatment of chronic heart failure: Executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26:1115-40.
2. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult-Summary Article A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005; 46:1116-43.
3. Mendez GF, Cowie MR. The epidemiological features of heart failure in developing countries: A review of the literature. Int J Cardiol 2001; 80:213-9.
4. Braunwald E, Grossman W. Clinical aspects of heart failure. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine 4th edn. Philadelphia: Saunders, 1992:444.
5. The CONSENSUS Trial Study Group.Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316:1429-35.
6. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342:821-8.
7. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327:669-77.
8. TRACE Study Group. A clinical trial of angiotensin converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. The Trandolapril Cardiac Evaluation (TRACE) Study. N Engl J Med 1995; 333:1670-6.
9. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353:2001-7.
10. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309-21.
11. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709-17.
12. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
13. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999; 353:9-13.
14. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334:1349-55.
15. National Institute for Clinical Excellence. Chronic heart failure. Management of chronic heart failure in adults in primary and secondary care. National Institute for Clinical Excellence 2003. [http://www.nice.org.uk/pdf/CG5NICEguidelines.pdf] (May 2008, date last accessed).
16. Anand IS, Florea VG. High output cardiac failure. Curr Treat Options Cardiovasc Med 2001; 3:151-9.
17. Poole-Wilson PA. Chronic heart failure: Cause, pathophysiology, prognosis, clinical manifestations, investigations. In: Julian DG, Camm AJ, Fox KF, Hall RJC, Poole-Wilson PA, eds. Diseases of the Heart, 1st edn. Bailliere-Tindall, 1989:24-36.
18. Riegger GA, Liebau G, Bauer E, Kochsiek K. Vasopressin and renin in high output heart failure of rats: Hemodynamic effects of elevated plasma hormone levels. J Cardiovasc Pharmacol 1985; 7:1-5.
19. Cohn JN, Levine TB, Francis GS, Goldsmith S. Neurohumoral control mechanisms in congestive heart failure. Am Heart J 1981; 102 (3 Pt 2):509-14.
20. Schrier RW. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (2). N Engl J Med 1988; 319:1127-34.
21. Pelliccia A, Maron BJ, Culasso F, Spataro A, Caselli G. Athlete's heart in women. Echocardiographic characterization of highly trained elite female athletes. JAMA 1996; 276:211-15.
22. Pelliccia A, Culasso F, Di Paolo FM, Maron BJ. Physiologic left ventricular cavity dilatation in elite athletes. Ann Intern Med 1999; 130:23-31.
23. Makan J, Sharma S, Firoozi S, Whyte G, Jackson PG, McKenna WJ. Physiological upper limits of ventricular cavity size in highly trained adolescent athletes. Heart 2005; 91:495-9.
24. Kervancioglu P, Hatipoglu ES. Echocardiographic evaluation of left ventricular morphology and function in young male football players and runners. Cardiol J 2007; 14:37-43.
25. Tumuklu MM, Ildizli M, Ceyhan K, Cinar CS. Alterations in left ventricular structure and diastolic function in professional football players: Assessment by tissue Doppler imaging and left ventricular flow propagation velocity. Echocardiography 2007; 24:140-8.
26. Tumuklu MM, Etikan I, Cinar CS. Left ventricular function in professional football players evaluated by tissue Doppler imaging and strain imaging. Int J Cardiovasc Imaging 2008; 24:25-35.
27. Anand IS, Chandrashekhar Y, Ferrari R, Poole-Wilson PA, Harris PC. Pathogenesis of oedema in chronic severe anaemia: Studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. Br Heart J 1993; 70:357-62.
28. Ni Z, Morcos S, Vaziri ND. Up-regulation of renal and vascular nitric oxide synthase in iron-deficiency anemia. Kidney Int 1997; 52 195-201.
29. Fowler NO, Holmes JC. Blood viscosity and cardiac output in acute experimental anemia. J Appl Physiol 1975; 39:453-6.
30. Bergrem H, Flatmark A, Simonsen S. Dialysis fistulas and cardiac failure. Acta Med Scand 1978; 204:191-3.
31. Anderson CB, Codd JR, Graff RA, Groce MA, Harter HR, Newton WT. Cardiac failure and upper extremity arteriovenous dialysis fistulas. Case reports and a review of the literature. Arch Intern Med 1976; 136:292-7.
32. Iwashima Y, Horio T, Takami Y, Inenaga T, Nishikimi T, Takishita S, et al. Effects of the creation of arteriovenous fistula for hemodialysis on cardiac function and natriuretic peptide levels in CRF. Am J Kidney Dis 2002; 40:974-82.
33. Ponsin JC, Levy B, Martineaud JP. Cardiac effects of the flow in the arteriovenous fistula. Study in 66 chronic hemodialysis patients. Presse Med 1983; 12:217-21.
34. Montejo BM, Perez M, De AJ, De la HC, Merino J, Aguirre C. High out-put congestive heart failure as first manifestation of Osler-Weber-Rendu disease. Angiology 1984; 35:568-76.
35. Brohee D, Franken P, Fievez M, Baudoux M, Henuzet C, Brasseur P, et al. High-output right ventricular failure secondary to hepatic arteriovenous microfistulae. Selective arterial embolization treatment. Arch Intern Med 1984; 144:1282-4.
36. Bourgeois N, Delcour C, Deviere J, Francois A, Lambert M, Cremer M, et al. Osler-Weber-Rendu disease associated with hepatic involvement and high output heart failure. J Clin Gastroenterol 1990; 12 236-8.
37. Robertson DJ. Congenital arteriovenous fistulae of the extremities. Ann R Coll Surg Engl 1956; 18:73-98.
38. Weber F.P. Angioma formation in connection with hypertrophy of limbs and hemihypertrophy. Brit J Derm 1907; 19:231-5.
39. Gwinn JL, Lee FA. Congestive heart failure secondary to peripheral arteriovenous malformation. Klippel-Trenaunay syndrome. Am J Dis Child 1977; 131:89-90.
40. Heistad DD, Abboud FM, Schmid PG, Mark AL, Wilson WR. Regulation of blood flow in Paget's disease of bone. J Clin Invest 1975; 55 69-74.
41. Henley JW, Croxson RS, Ibbertson HK. The cardiovascular system in Paget's disease of bone and the response to therapy with calcitonin and diphosphonate. Aust N Z J Med 1979; 9:390-7.
42. Arnalich F, Plaza I, Sobrino JA, Oliver J, Barbado J, Pena JM, et al Cardiac size and function in Paget's disease of bone. Int J Cardiol 1984; 5:491-505.
43. McBride W, Jackman JD Jr, Gammon RS, Willerson JT. High-output cardiac failure in patients with multiple myeloma. N Engl J Med 1988; 319:1651-3.
44. Inanir S, Haznedar R, Atavci S, Unlu M. Arteriovenous shunting in patients with multiple myeloma and high-output failure. J Nucl Med 1998; 39:1-3.
45. Fowler NO, Wescott RN, Scott RC, Hess E. The cardiac output in chronic cor pulmonale. Circulation 1952; 6:888-93.
46. Anand IS, Chandrashekhar Y, Ferrari R, Sarma R, Guleria R, Jindal SK, et al. Pathogenesis of congestive state in chronic obstructive pulmonary disease. Studies of body water and sodium, renal function, hemodynamics, and plasma hormones during edema and after recovery. Circulation 1992; 86:12-21.
47. Lewis BS, Ehrenfeld EN, Lewis N, Gotsman MS. Echocardiographic LV function in thyrotoxicosis. Am Heart J 1979; 97:460-8.
48. Wilson BE, Newmark SR. Thyrotoxicosis-induced congestive heart failure in an urban hospital. Am J Med Sci 1994; 308:344-8.
49. Froeschl M, Haddad H, Commons AS, Veinot JP. Thyrotoxicosis-an uncommon cause of heart failure. Cardiovasc Pathol 2005; 14:24-7.
50. Blasco PF, Perez MR, Roman GF, Lopez de Letona JM, Villares P, Jimenez AI. High output heart failure and pulmonary acute edema as presentation of thyrotoxicosis secondary to toxic multinodular goiter. Rev Clin Esp 2004; 204:608-9.
51. Watanabe H, Okamura K, Chinushi M, Furushima H, Tanabe Y, Kodama M, et al. Clinical characteristics, treatment, and outcome of tachycardia induced cardiomyopathy. Int Heart J 2008; 49 39-47.
52. Peake ST, Mehta PA, Dubrey SW. Atrial fibrillation-related cardiomyopathy: A case report. J Med Case Rep 2007; 1:111.
53. Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med 1993; 328:1471-7.
54. Rotheram EB Jr. High output congestive heart failure in septic shock. Chest 1989; 95:1367-8.
55. Bone RC, Grodzin CJ, Balk RA. Sepsis: A new hypothesis for pathogenesis of the disease process. Chest 1997; 112:235-43.
56. Moncada S, Palmer RM, Higgs EA. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43 109-42.
57. Rees DD, Monkhouse JE, Cambridge D, Moncada S. Nitric oxide and the haemodynamic profile of endotoxin shock in the conscious mouse. Br J Pharmacol 1998; 124:540-6.
58. Akbarian M, Yankopoulos NA, Abelmann WH. Hemodynamic studies in beriberi heart disease. Am J Med 1966; 41:197-212.
59. Ayzenberg O, Silber MH, Bortz D. Beriberi heart disease. A case report describing the haemodynamic features. S Afr Med J 1985; 68 263-5.
60. Alpert MA. Obesity cardiomyopathy: Pathophysiology and evolution of the clinical syndrome. Am J Med Sci 2001; 321:225-36.
61. Alpert MA, Hashimi MW. Obesity and the heart. Am J Med Sci 1993; 306:117-23.
62. Galinier M, Pathak A, Roncalli J, Massabuau P. Obesity and cardiac failure. Arch Mal Coeur Vaiss 2005; 98:39-45.
63. Barzizza F. Obesity and the heart. Minerva Gastroenterol Dietol 2001; 47:229-34.
64. Contaldo F, Pasanisi F, Finelli C, de Simone G. Obesity, heart failure and sudden death. Nutr Metab Cardiovasc Dis 2002; 12:190-7.
65. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347:305-13.